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http://www.malariajournal.com/content/13/1/255RESEARCH Open AccessIncidence of malaria-related fever and
morbidity due to Plasmodium falciparum among
HIV1-infected pregnant women: a prospective
cohort study in South Benin
Alexandre Duvignaud1,2,3*, Lise Denoeud-Ndam1,2, Jocelyn Akakpo4,5, Komlan V Agossou6, Aldric Afangnihoun7,
Didier G Komongui8, Félix Atadokpédé9, Lucien Dossou-Gbété10, Pierre-Marie Girard11,12, Djimon-Marcel Zannou4,5
and Michel Cot1,2Abstract
Background: Malaria and HIV are two major causes of morbidity and mortality among pregnant women in
sub-Saharan Africa. Foetal and neonatal outcomes of this co-infection have been extensively studied. However,
little is known about maternal morbidity due to clinical malaria in pregnancy, especially malaria-related fever,
in the era of generalized access to antiretroviral therapy and anti-malarial preventive strategies.
Methods: A cohort study was conducted in order to estimate the incidence rate and to determine the
factors associated with malaria-related fever, as well as the maternal morbidity attributable to malaria in a
high-transmission setting of South Benin among HIV-infected pregnant women. Four-hundred and thirty-two
women who participated in a randomized trial testing strategies to prevent malaria in pregnancy were included
and followed until delivery, with at least three scheduled visits during pregnancy. Confirmed malaria-related fever
was defined as axillary temperature >37.5°C and a concomitant, positive, thick blood smear or rapid diagnostic test
for Plasmodium falciparum. Suspected malaria-related fever was defined as an axillary temperature >37.5°C and the
concomitant administration of an anti-malarial treatment in the absence of parasitological investigation.
Results: Incidence rate for confirmed malaria-related fever was of 127.9 per 1,000 person-year (PY) (95%
confidence interval (CI): 77.4-211.2). In multivariate analysis, CD4 lymphocytes (Relative Risk (RR) for a 50 cells/mm3
variation = 0.82; CI: 0.71-0.96), antiretroviral treatment started before inclusion (RR = 0.34; CI: 0.12-0.98) and history of
symptomatic malaria in early pregnancy (RR = 7.10; CI: 2.35-22.49) were associated with the incidence of confirmed
or suspected malaria-related fever. More than a half of participants with parasitaemia were symptomatic, with fever
being the most common symptom. The crude fraction of febrile episodes attributable to malaria was estimated
at 91%.
Conclusions: This work highlights that malaria is responsible for a substantial morbidity in HIV-infected pregnant
women, with cellular immunodepression as a major determinant, and establishes the possible advantage offered
by the early initiation of antiretroviral treatment.
Trial registration: PACOME Study has been registered under the number NCT00970879.
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The consequences of malaria in pregnancy (MiP) for the
foetus and the newborn have been extensively studied.
MiP increases the risk of low birth weight (LBW), which
is the most important determinant of mortality during
the first year of life in African infants [1]. In mothers, MiP
increases the risk of maternal anaemia [2-4]. Co-infection
with HIV and Plasmodium falciparum has been associated
with an increased risk of malaria-related fever among
HIV-infected adults living in Uganda, especially in those
with severe immunodepression [5,6]. The consequences of
MiP are more severe [7-9], intermittent preventive treat-
ment (IPTp) with sulphadoxine-pyrimethamine (SP) is
less effective [10] and resistances to antifolates are more
frequent [11] among HIV-infected than in HIV-uninfected
women. Additionally, the risk of unfavourable outcomes
related to MiP remains high in HIV-infected multigravid
women [7,8,12]. Finally, the mother-to-child transmission
of HIV could be facilitated [13]. One explanation for that
could be the increase of HIV viral load during malaria-
related fever episodes [14]. However, other studies found
no [15,16] or an equivocal [17] association between pla-
cental malaria and mother to child transmission of HIV.
Despite this body of knowledge, data concerning the
maternal morbidity attributable to P. falciparum infection
in HIV-infected pregnant women, especially fever, are
scarce. Incidence data on clinical malaria in this population
are rare, ancient, and do not reflect the actual standard of
care towards antiretroviral therapy access and anti-malarial
preventive measures [18]. Moreover, this issue have never
been studied longitudinally regarding potential associated
factors [8,12].
To avoid the adverse consequences of MiP, the World
Health Organization (WHO) now recommends IPTp
with a single dose of SP at each antenatal visit for all
pregnant women, irrespectively of their HIV status [19].
However, due to the spread of resistances to antifolates
in Africa [20-22], the evaluation of alternative strategies
is urgently needed. The PACOME project was a random-
ized trial comparing daily cotrimoxazole to intermittent
preventive treatment with mefloquine for the prevention
of malaria in HIV-infected pregnant women living in
Benin. It consisted of a prospective cohort of 432 HIV-1
infected pregnant women living in an urban-suburban
area of South Benin [23]. This follow-up offered the
opportunity to assess longitudinally malaria-related fever
incidence rate and associated factors as well as the
morbidity attributable to P. falciparum infection in this
population.
Methods
Study site and participants
The study took place in the Littoral department of
Benin, in Cotonou (the economical capital of Benin) andits suburbs, and in Porto Novo (the administrative cap-
ital), both located on the Atlantic coast of the Guinean
Gulf, at the extreme south of the country. Regarding
malaria, the south of Benin is characterized by a high
perennial transmission of P. falciparum with two peaks
during the rainy seasons, from April to June, and from
September to November. The mean entomological inocu-
lation rate was found to be 5.3 infective bites per person
and per year in a close rural area [24] and the incidence of
symptomatic malaria was 8.7% among adults older than
15 years living in the district of Cotonou in 2011 [25].
Among pregnant women, the nationwide prevalence of
HIV infection was 1.6% in 2011. Of note, it was higher in
the Littoral department (district of Cotonou), where it
reached 3.4% [26].
HIV care centers and antenatal clinics (ANC) from five
hospitals were involved in the study: Centre National
Hospitalier Universitaire Hubert Koutoukou Maga, Hôpital
d’Instruction des Armées de Cotonou, Hôpital de Zone de
Suru-Léré, Hôpital Mère Enfant de la Lagune, and Clinique
de Porto Novo. The main occupation of the women in this
area is informal trading.
Midwives were recruited and trained as research assis-
tants to fill questionnaires and to collect blood samples
from the study participants. Local midwives, nurses and
physicians in charge of the HIV care units and ANC
worked in close collaboration with the research assistants.
Study design
The study population consisted of 432 women enrolled in
the PACOME clinical trial, between December 2009 and
December 2011 [23]. The PACOME trial has been de-
scribed in detail elsewhere [23]. Briefly, it was a random-
ized, non-blinded, non-inferiority trial (NCT00970879)
aiming to compare the efficacy of two strategies for mal-
aria prevention in HIV-infected pregnant women. The
participants were randomized to receive either a daily
cotrimoxazole prophylaxis throughout the course of preg-
nancy, or an IPTp with three intakes of mefloquine,
between 16 and 28 weeks, 24 and 32 weeks, then 28 and
36 weeks of gestation. In case of low CD4 lymphocytes
count (below 350 cells/mm3) or advanced HIV disease
(WHO staging ≥2), all women received cotrimoxazole for
the prevention of opportunistic infections, associated or
not with mefloquine depending on the treatment group.
Combined antiretroviral therapy (ART) was prescribed for
the prevention of mother-to-child HIV transmission or
for maternal health, according to national guidelines. The
primary endpoint of the trial was the prevalence of placen-
tal malaria. All enrolled women had to be HIV1-infected
and between 16 and 28 weeks of gestation, to live in the
study area, to have planned to deliver at the hospital, to
have signed an informed consent and to have no contra-
indication to the study drugs.
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were evaluated at three antenatal care visits scheduled at
least one month apart between 16 and 28, 24 and 32, 28
and 36 weeks, and at delivery. When sick, women were
also encouraged to attend the clinic for free-of-charge
diagnosis and treatment. Socio-economic data and ob-
stetrical history were recorded at enrolment as well as
HIV disease information. At each visit and at delivery,
obstetrical, malaria and HIV-related information were
also collected. In addition to anti-malarial preventive
treatments, intravenous quinine was administered in
case of severe malaria. A three-day treatment of arteme-
ther-lumefantrine (Coartem® Novartis) was administered in
case of non-severe malaria, except for women with asymp-
tomatic or low parasitaemia (<1,000 parasites/μl) who
received a dose of mefloquine IPTp the same day. Op-
portunistic infections of HIV were treated according to
national guidelines.
Laboratory procedures
Laboratory procedures have been extensively described
elsewhere [23]. Briefly, for malaria diagnosis, thick and
thin blood smears were performed on each scheduled
visit and at additional visits in case of symptoms suggest-
ive of malaria. Blood smears were stained with Giemsa
and microscopically examined for the detection of para-
sites. Malaria rapid diagnostic tests (RDTs) were also
performed at each visit, scheduled or not, even in the
absence of symptoms suggestive of malaria. The test
used was Parascreen® (Rapid Test for Malaria Pan/Pf,
Zephyr Biomedicals, Verna, Goa, India), a combined test
detecting the histidine-rich protein 2 (HRP2) specific of P.
falciparum and the Plasmodium lactate dehydrogenase
(pan pLDH). HIV viral load was planned to be assessed at
inclusion and delivery by real-time quantitative PCR using
2000 Abbott thermocyclers (Abbott Laboratories, Abbott
Park, IL) provided by the National AIDS Control Pro-
gramme, with a 40 copies per milliliter detection thresh-
old. Absolute CD4 count and percentage were planned to
be assessed at each visit by Cyflow (Partec, Münster,
Germany) or Facscount (Beckton Dickinson, Franklin
Lakes, NJ) cytometer.
Definitions
Fever was defined as an axillary temperature >37.5°C. A
case of confirmed malaria-related fever was defined as
an axillary temperature >37.5°C and a concomitant,
positive thick blood smear, or positive HRP2 band of the
RDT in the absence of symptoms or findings indicating
other infections. A case of suspected malaria-related
fever was defined as an axillary temperature >37.5°C and
the concomitant administration of anti-malarial therapy
in the absence of parasitological investigation and of
symptoms or findings indicating other infections.Statistical analysis
Data capture, cleaning and validation were perfor-
med using Microsoft Access 2003. Data analysis was
performed using SAS version 9.2 for Windows (SAS
Institute, Cary, NC, USA) and a two-sided 5% alpha
risk.
First, women’s medical and socio-economic characteris-
tics, the initial clinical presentation and, when known, the
diagnoses associated with febrile episodes were described.
The diagnoses associated with febrile episodes were com-
pared according to the severity of cellular immunodepres-
sion. Incidence rates for confirmed malaria-related fever,
suspected malaria-related fever and total malaria-related
fever (confirmed or suspected) were estimated and repor-
ted symptoms associated with confirmed malaria were
described. A sample size of 385 women was necessary to
obtain an estimation of the incidence rate of malaria-
related fever with 10% relative precision and a confidence
level of 95% [27]. After univariate analysis comparing the
characteristics of women with confirmed, suspected or
without malaria-related fever (Fisher’s exact test for
proportions and Wilcoxon’s exact test for quantitative
variables), a multivariate Poisson regression was used
to determine the association between women’s medical
and socio-economic characteristics and the incidence of
both outcomes (confirmed, then confirmed or suspected
malaria-related fever). The initial models included the co-
variates with P-value <0.3 in univariate Poisson regression
and those forced a priori: age, baseline CD4 cell count (as
a quantitative variable assessed at inclusion), type of
malaria chemoprophylaxis, study centre, parity, season at
delivery. A stepwise procedure was used to select the
strongest parsimonious models while searching for pos-
sible confusion or interaction between covariates. In the
final multivariate analysis, a P-value <0.05 was considered
significant. A sensitivity analysis was performed for the
final model considering confirmed malaria-related fever as
the dependent variable, first excluding suspected malaria
fever cases from the analysis, then considering them in
the control group.
Finally, the crude fraction of febrile episodes attributable
to malaria among participants who were infected by P. fal-
ciparum from positive thick blood smear obtained on the
occasion of scheduled visits was estimated. For this pur-
pose, the following equation was used: AFe = (Re – R0)/
Re, with AFe the attributable fraction of risk in exposed,
Re the risk (of fever) in exposed and R0 the risk (of fever)
in unexposed. Exposure was defined as having a positive
blood smear for P. falciparum at the considered time
point. The risk was defined as the number of either ex-
posed or unexposed women having fever at the consid-
ered time point divided by the corresponding exposed or
unexposed population (febrile and afebrile) at the same
time point.
Table 1 Baseline characteristics of the 432 pregnant
women who participated in the PACOME trial
Category Subcategory N (%) or
mean (SD)*
Sociodemographic
characteristics
Health centre CNHU 136 (31.5)
HIA 76 (17.6)
CLP 29 (6.7)
HZ de Suru Léré 146 (33.8)
HOMEL 45 (10.4)
Age (years) (N = 431) 29.2 (4.7)
Education None or unknown 117 (27.1)
Primary 153 (35.3)
Secondary 128 (29.8)
University 34 (7.8)
Marital status Single 25 (5.8)
Married
(monogam)
272 (63.0)
Married (polygam) 131 (30.2)
Other or unknown 4 (1.0)
General and obstetric
characteristics
Obesity (BMI ≥30 kg/m2) (N = 427) 52 (12.2)
Sickle cell trait (N = 267) Homozygote (SS) 16 (6.0)
Heterozygote (AS) 26 (9.7)
Primigravid 50 (11.6)
Number of live born 1.7 (1.5)
Gestational age at inclusion
(weeks)
21.7 (3.8)
Symptomatic malaria in early
pregnancy before inclusion
(N = 424)
45 (10.6)
HIV–related characteristics
Time since HIV diagnosis (months)* 15 (1–42)*
WHO staging 1 303 (70.1)
2 62 (14.4)
3 65 (15.1)
4 2 (0.5)
CD4 cell count (/mm3)* 342
(230–491)*
Undetectable viral load (N = 257) 82 (31.9)
Cotrimoxazole started before
the ongoing pregnancy
(N = 430)
204 (47.4)
Antiretroviral therapy started
before inclusion (N = 429)
222 (51.8%)
*Values presented are median and interquartile range.
CNHU, Centre National Hospitalier Universitaire Hubert Koutoukou Maga; HIA,
Hôpital d’Instruction des Armées de Cotonou; HOMEL, Hôpital Mère Enfant de
la Lagune; CLP, Clinique Louis Pasteur; HZ, Hôpital de Zone.
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The PACOME trial has been ethically approved both in
France and in Benin, respectively by the ‘Comité consul-
tatif de déontologie et d’éthique de l’IRD’, and by the
‘Comité national provisoire d’éthique pour la recherche
en santé’, of the Beninese Faculté des Sciences de la
Santé. The procedures followed were in accordance with
the Helsinki Declaration of 1975, as revised in 2000.
Results
Baseline characteristics
Between December 2009 and December 2011, 432 par-
ticipants were randomized in the PACOME study among
533 screened HIV-1 infected pregnant women. Of these,
140 received cotrimoxazole, irrespective of their treatment
group, due to severe immunodepression or advanced HIV
disease [23].
General characteristics of the participants at inclusion
are summarized in Table 1. The mean age was 29.2 years
(standard deviation (SD) 4.7 years) and mean gestational
age was 21.7 weeks. Fifty-two per cent of women had a
CD4 count below 350 cells/mm3, 52% had already initi-
ated ART and HIV RNA viral load was undetectable in
82 (31.9%) women among 257 for whom this assay had
been performed. Due to maintenance problems and fi-
nancial shortages in National AIDS Control Programme
laboratory, this test could not be performed for all women.
For more details regarding ART regimen received by par-
ticipating women see Additional file 1.
Follow-up
The 432 women who participated in the PACOME study
totalized 130.9 person-years (PY) follow-up with a mean
duration of 15.8 weeks (SD 5.6). Nine women (2.1%)
were lost to follow-up just after their first visit and were
not considered in incidence calculation. Recruitment
and follow-up in the PACOME study have been detailed
elsewhere. Briefly, 393 women (91%) were followed until
delivery, with a median of 4 visits (interquartile range: 3
to 5). No death was imputed to the infection with P.
falciparum among participants.
Febrile episodes
Overall, 68 participants (16%) experienced a total of 86
febrile episodes, 17 of whom were associated with P. fal-
ciparum detection (positive HRP2 RDT and thick smear
in 11 cases and isolated positive HRP2 RDT for six add-
itional cases). Three febrile episodes were considered as
suspected malaria by the caregivers and were treated by
anti-malarial treatment. In total, 20 (23%) febrile episodes
were referred as confirmed or suspected malaria-related
fever. Six (30%) of these episodes, all related to confirmed
malaria-related fever, occurred during the period between
screening and inclusion of the participants, i.e. before the
Table 3 Symptoms declared by the PACOME study
participants with confirmed Plasmodium falciparum
infection* (n = 45)
N (%)
Positive RDT or TBS
(n = 45)
Positive TBS
(n = 32)
Asymptomatic 21 (46.7) 14 (43.8)
Fever 17 (37.8) 11 (34.4)
Isolated fever 6 (13.3) 2 (6.25)
Headache 7 (15.6) 6 (18.8)
Asthenia 6 (13.3) 6 (18.8)
Nausea or vomiting 6 (13.3) 5 (15.6)
Muscular stiffness 3 (6.7) 3 (9.4)
Shivers 2 (4.4) 2 (6.3)
Cough 1 (2.2) 1 (3.1)
*assessed by rapid diagnostic test (RDT) or thick blood smear (TBS).
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sentations of the other febrile episodes are summarized in
Table 2. Eleven women experienced two febrile episodes
(accounting for four confirmed malaria-related fever epi-
sodes, two of them occurring in the same woman, and
one suspected malaria-related fever episodes), one woman
experienced three febrile episodes (two of them being as-
sociated with P. falciparum) and one woman experienced
six febrile episodes (no malaria-related fever).
Plasmodium falciparum infections related morbidity
Forty-five non-recurrent episodes of confirmed infection
with P. falciparum were reported during the PACOME
trial. The symptoms reported by the women during
these infections are summarized in Table 3. More than a
half of them reported at least one symptom. Fever was
the most frequently reported, present in one-third of
cases. Headache, asthenia, nausea and vomiting were also
reported. Fever was present in 46% (12/26) of the women
infected with P. falciparum and having CD4 < 350/mm3
compared to 26% (5/19) of the women infected with P.
falciparum and having CD4 ≥ 350/mm3 (p = 0.22, Fisher
exact test).
On the other hand, the proportion of febrile episodes
referred as confirmed or suspected malaria-related fever
was higher in women with a CD4 cell count <350/mm3
(31%) than in women with a CD4 cell count ≥350/mm3
(14%, p = 0.03). The distribution of febrile episodes and
their suspected origin according to CD4 level are sum-
marized in Table 4.
Data regarding P. falciparum parasitaemia were avail-
able for 1,130 out of 1,626 scheduled visits. Thirty-one
episodes of parasitaemia (non-recurrent positive thick
smear) and 42 febrile episodes were recorded during
scheduled visits. The distribution of the 1,130 visits
according to the presence of parasitaemia or fever is
summarized in Table 5. On this basis, the crude fractionTable 2 Clinical presentation of febrile episodes (n = 86)
and diagnoses in the PACOME participants (N = 432)
Clinical presentation - diagnosis N (%)
Confirmed malaria 17 (19.8)
Isolated positive RDT 6
Both RDT and thick blood smear positive 11
Presumed malaria 3 (3.5)
Non-malaria fever 66 (76.7)
Respiratory symptoms (including cough and dyspnea)* 5
Digestive symptoms (nauseas, vomiting, diarrhea) or
pelvian discomfort
4
Cellulitis 1
Isolated fever 56
*one case of tuberculous pleuresia.
RDT, rapid diagnostic test.of febrile episodes attributable to the infection with P.
falciparum was 91%. In the 32 parasitaemic patients,
the association between febrile condition and parasite
density was investigated, when data were available.
The median parasite density in febrile, parasitaemic
patients was 1,000 trophozoïtes/mm3 (interquartile range
(659–9,762), n = 10) versus 478 (interquartile range (157–
1,422), n = 21) in afebrile, parasitaemic patients (p = 0.22,
Wilcoxon exact test).Incidence rates estimations and associated factors
Unadjusted incidence rates for febrile episodes, confirmed
malaria-related fever and suspected malaria-related fever
are displayed in Table 6. The incidence rate of confirmed
malaria-related fever was 127.9 for 1,000 PY (IC 95 =
(77.4-211.2)) in the study population, which approximately
corresponds to a proportion of 1/10 HIV-infected women
undergoing malaria-related fever during the 40 weeks of
gestation.Table 4 Febrile episodes diagnoses (n = 86) in PACOME
participants (N = 432) according to CD4 level
Diagnosis N (%) p-value*
CD4 < 350 by
mm3 (n = 38)
CD4 ≥ 350 by
mm3 (n = 30)
Confirmed malaria 12 (24.5) 5 (13.5) 0.17
Isolated positive RDT 5 (10.2) 1 (2.7)
Both RDT and thick
blood smear positive
7 (14.3) 4 (10.8)
Suspected malaria 3 (6.1) 0 (0) 0.25
Confirmed or
suspected malaria
15 (30.6) 5 (13.5) 0.03
Total 49 37
*Fisher exact test.
Table 5 Distribution of scheduled visits according to the
presence of Plasmodium falciparum parasitaemia* and
fever
Parasitaemia Total
Yes No
Febrile episode Yes 10 32 42
No 21 1,067 1,088
Total 31 1,099 1,130
*assessed by systematic thick blood smear.
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iate analysis, baseline CD4 cell count at inclusion, consid-
ered as a dichotomic (threshold at 350 cells/mm3) or as a
quantitative variable (p = 0.03) and having experienced
symptomatic malaria (declarative data) at the beginning of
the pregnancy (p = 0.001) were associated with confirmed
or suspected malaria-related fever.
In the initial multivariate Poisson regression, modeling
factors associated with confirmed or suspected malaria-
related fever incidence, variables introduced apart from
those forced a priori were the following: ART started
before inclusion, complete follow-up until delivery,
gestational age at inclusion and having experienced symp-
tomatic malaria at the beginning of the pregnancy. In the
final models (Table 7), confirmed malaria-related fever was
associated to CD4 cell count at inclusion and having expe-
rienced symptomatic malaria at the beginning of the preg-
nancy. Confirmed or suspected malaria-related fever was
associated with lower CD4 cell count at inclusion, having
started antiretroviral therapy before the inclusion and hav-
ing experienced symptomatic malaria at the beginning of
the pregnancy. Of note, the type of antimalarial preventive
treatment was not associated to malaria-related fever inci-
dence. No interaction between the selected variables was
evidenced. These results remained unchanged when per-
forming sensitivity analysis (see Additional file 2).
Discussion
A study conducted in Rwanda during the early 1990s
compared malaria incidence during the third trimester of
pregnancy and six months post-partum among women
infected or not by HIV [18]. The women were receiving
neither antiretroviral therapy nor malaria preventive
measures. For these reasons and due to definitionsTable 6 Incidence rates of febrile episodes and malaria-
related fever for 1,000 PY (n = 432) (95% confidence
interval)
All febrile episodes 646.9 (497.8-840.7)
Confirmed malaria 127.9 (77.4-211.2)
Presumed malaria 22.6 (6.8-75.3)
Confirmed or presumed malaria 150.4 (94.9-238.5)discrepancies, the overall incidence of clinical malaria
infection was far higher than in the present study (6.2
per 100 women-months, i.e. 744 per 1,000 women-
years, in the HIV-positive group and 3.5 per 100 women-
months, i.e. 420 per 1,000 women-years, in the HIV-
negative group, RR = 1.7, 95% CI = 1.4 – 2.3). Two
other cross-sectional studies on malaria-related mor-
bidity during pregnancy were carried out in Eastern Af-
rica in the 1990s. They reported an increased frequency of
anti-malarial drugs [8,12] use and of symptomatic malaria
[12] in HIV seropositive compared to HIV seronegative
pregnant women. In the first one, participants received
IPTp with two doses of SP, in accordance with local
guidelines. In both studies, pregnant women had no
access to ART. In the present work, almost all women
were receiving ART and they all received anti-malarial
chemoprophylaxis within the frame of the PACOME trial
(IPTp with mefloquine, daily cotrimoxazole or both). A
noteworthy difference between the above-mentioned stud-
ies and this work is the earliness, the length and the qual-
ity of the follow-up. Of note, a similar analysis performed
in a real life sample of HIV-infected pregnant women
followed-up in the same centers, but not participating in
the PACOME trial, provided comparable results for mal-
aria-related fever incidence rates (Additional file 3). There-
fore this study population is well representative of the
population of HIV-infected pregnant women living in an
urban area with a high transmission of P. falciparum, in
the era of generalized ART, insecticide-treated bed nets
use and IPTp.
The first important result is that among HIV-infected
pregnant women receiving ART and adequate prevention
of MiP, the incidence of malaria-related fever remained
substantial. Although the malaria transmission conditions
and population were not similar and the follow-up was
much closer in the present study, one can compare the
incidence rate of 127.9 per 1,000 PY for confirmed mal-
aria-related fever found in this study’s population to the
101.6 per 1,000 PY found by French et al. in a population
of HIV-infected adults with no access to ART or anti-
malarial chemoprophylaxis living in Uganda [5]. Despite
this, a residual under-reporting cannot be ruled out for
some women with mild fever who might not have sought
medical care.
This work confirms the role of CD4 immunodepression
as a major determinant for the risk of malaria-related fever
in HIV-infected pregnant women, already established in
HIV-infected adults [5,6]. Furthermore, it suggests that
febrile episodes could be more frequently related to malaria
in the most immunocompromised women (cf. Table 4).
However, this result has to be taken with caution, since it
includes both confirmed and suspected malaria-related
fever. An information bias related to a differential mis-
classification of suspected malaria-related fever episodes
Table 7 Factors associated with confirmed malaria fever incidence in the PACOME participants Multivariate Poisson
regression*
Variable Outcome
Confirmed malaria (N = 410) Confirmed or suspected malaria (N = 413)
Relative risk 95% CI Relative risk 95% CI
Age (for 5 years) 1.25 (0.70-2.27) 1.27 (0.74-2.18)
CD4 (for 50 cells/mm3) 0.83 (0.71-0.99) 0.82 (0.71-0.96)
Type of anti-malarial chemoprophylaxis
(cotrimoxazole alone vs mefloquine IPTp +/− cotrimoxazole)
1.72 (0.61-4.89) 2.24 (0.83-6.07)
Antiretroviral therapy started before inclusion 0.39 (0.12-1.21) 0.34 (0.12-0.98)
Symptomatic malaria during the early pregnancy (before inclusion) 8.89 (2.68-29.52) 7.1 (2.35-21.49)
Primiparity 1.09 (0.21-5.58) 0.84 (0.17-4.16)
Delivery during the rainy season 0.55 (0.20-1.54) 0.63 (0.25-1.60)
*adjusted on the health centre.
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occurred. Moreover, it is difficult to establish a causal
relationship between febrile episodes and malaria in
this population. In high transmission areas, an immuno-
competent host can be infected with P. falciparum while
experiencing fever or symptoms induced by other patho-
gens. In order to improve the specificity of malaria-related
fever diagnosis, it has been proposed to take into account
the parasite density in the definition of confirmed cases as
well as for the estimation of the fraction of febrile episodes
attributable to P. falciparum in parasitaemic subjects [28].
Among HIV-infected adults experiencing a febrile episode,
it has been shown that the lower the CD4 cell count, the
higher the parasite density [5]. Unfortunately, it was im-
possible to use such an approach in this study, because of
the sparse available data on parasite densities. Moreover,
when available, parasite densities were generally moderate
or low and not very different according to the symptom-
atic status, probably because of preventive treatment.
No difference was found in malaria-related fever inci-
dence according to the type of anti-malarial chemoprophy-
laxis. The high proportion of malaria-related fever episodes
(30%) which occurred before the first intake of the trial’s
preventive treatment is a possible explanation. However, a
further analysis excluding these cases found similar results.
The PACOME trial, whose primary endpoint was the pla-
cental infection by P. falciparum at delivery, concluded to
the non-inferiority of daily cotrimoxazole compared to
mefloquine IPTp in the subtrial with mandatory cotrimox-
azole due to advanced HIV disease. In the subtrial without
mandatory cotrimoxazole, the target sample size was not
reached so it was impossible to assess non-inferiority [23].
All of these results suggest that the levels of protection
conferred by the different strategies used in this population
are probably not very different.
Having experienced symptomatic malaria in early
pregnancy appeared to be strongly associated with the
incidence of malaria-related fever during the follow-upin multivariate analysis. The hypothesis was made that
this variable reflects the role of unmeasured factors, for
instance, an overall higher exposure to malaria transmis-
sion in symptomatic pregnant women. Delivering during
the rainy season did not constitute a risk factor for
malaria-related fever in this work. The majority of the
participants were living in an urban area, less favourable
to malaria transmission than a rural setting. Addition-
ally, the time of delivery may not be an adequate indica-
tor of the exposure to malaria associated with seasonal
variations throughout the whole pregnancy.
In the multivariate analysis of factors associated with
confirmed and suspected malaria-related fever episodes,
ART initiated before inclusion appeared to be a protect-
ive factor, even after adjusting for baseline CD4 count.
This could be due to an important gain in CD4 during
follow-up for women under ART for a short time before
inclusion. The only CD4 cell count included in the ana-
lysis was performed at baseline because of frequent
missing data for further assessments, so it is not possible
to further elucidate this question. This finding represents
an additional reason to start ART as early as possible
during the pregnancy especially in women newly diag-
nosed of their HIV infection. Another study carried out
previously in the same cohort confirmed the benefit of
early ART during pregnancy in order to reach an un-
detectable HIV viral load at delivery and to minimize the
risk of mother-to-child transmission of the virus [29]. The
control of HIV replication could also play an important
part in the observed association between longer ART
duration and decreased malaria fever incidence.
An earlier study in Uganda had already shown that
ART associated to daily cotrimoxazole was protective
against malaria-related fever, compared to daily cotrimox-
azole alone, in a population of HIV-infected adults and
adjusted for the CD4 cell count [30]. In the Ugandan
study, as in the present study, the time since seroconver-
sion and the CD4 slope were not taken into account.
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infection severity and thus the possibility to evaluate the
benefit of early ART intake on the risk of symptomatic
malaria.
MiP in HIV-negative pregnant women living in a high-
transmission area is generally considered to be asymptom-
atic [31]. However, previous studies suggested that MiP is
frequently symptomatic and responsible for a high mor-
bidity in HIV-infected pregnant women, especially with
low CD4 [5,9]. Overall, more than one third of the
PACOME participants who were infected by P. falciparum
on a systematically performed blood smear were febrile at
the same time. Interestingly, the frequency of fever among
women infected with P. falciparum was almost doubled
when the CD4 count was low, although not significantly.
The efficacy of malaria preventive measures and a possible
lack of power are possible explanations. It could be valu-
able to systematically record malaria-related maternal
morbidity in all longitudinal studies aiming to assess new
strategies for the prevention of MiP, especially in vulner-
able populations, such as HIV-infected pregnant women.
From this point of view, studies including both HIV-
infected and uninfected pregnant women are highly suit-
able to allow direct comparison.
Conclusions
In Benin, malaria-related fever is responsible for a substan-
tial morbidity among HIV-infected pregnant women in
spite of generalized access to ART and adequate anti-
malarial prevention. More than a quarter of febrile epi-
sodes were related to malaria in the study population. This
justifies prompt and accurate diagnosis and treatment of
malaria within the frame of antenatal care programmes.
The severity of immunodepression, which has already been
shown to be major risk factor for malaria-related morbidity
in HIV-infected adults, is of special concern among HIV-
infected pregnant women. As a consequence, women with
low CD4 cell count should be prioritized regarding access
to ARTand anti-malarial chemoprophylaxis.
Indeed, the earliness of ART during the pregnancy
could be an efficient measure for the prevention of mal-
aria-related morbidity in this population. From a patho-
physiological point of view, the hypothetic restoration of a
parity-dependent phenomenon for the acquisition of anti-
malarial protective immunity under ART should be further
assessed. It could be a strong argument for immediate and
definitive ART upon diagnosis of HIV infection for all
pregnant women (option B + of the WHO) [32]. It also
raises the problem of global implementation of ‘test and
treat’ strategies in resource-limited settings. Finally, women
who have already presented a malaria-related fever episode
during their pregnancy should be followed more closely
because they are likely to present re-infections with
P. falciparum.Additional files
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